Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
GSK flags up pipeline as HIV drugs help it beat profit forecasts

GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts.

Published
30 July 2015
From
Reuters
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable

Published
28 July 2015
By
Liz Highleyman
New NNRTI doravirine suppresses HIV as well as efavirenz but with fewer central nervous system side-effects

Merck's next-generation NNRTI doravirine (formerly known as MK-1439) was found to be as effective as efavirenz at suppressing HIV replication, but half as many study participants taking doravirine experienced drug-related

Published
23 July 2015
By
Liz Highleyman
Next-generation maturation inhibitor BMS-955176 shows good antiviral activity in combination with atazanavir

The next-generation HIV maturation inhibitor BMS-955176 was well-tolerated and suppressed HIV viral load as well as standard antiretroviral therapy when used in a combination with atazanavir (Reyataz)

Published
22 July 2015
By
Liz Highleyman
Targets proliferate in HIV cure research

The Towards an HIV Cure two-day symposium has become a fixture in advance of the International AIDS Society conferences and this one featured a more varied range

Published
21 July 2015
By
Gus Cairns
New drug holds out promise of long-term control or even cure of HIV

Scientists at the Scripps Research Institute in California have discovered a new type of drug that may permanently inhibit HIV from becoming reactivated in the cells that

Published
18 July 2015
By
Gus Cairns
TAG Pipeline Report

2015 report on the pipeline for new HIV, HCV and TB drugs.

Published
17 July 2015
From
TAG
Evidence of HIV Suppression With PRO 140 Monotherapy Reaching Nearly 11 Months

CytoDyn Inc.(OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that its ongoing extension study of PRO 140 monotherapy in HIV-infected patients has shown complete viral-load suppression for nearly 11 months.

Published
16 July 2015
From
CytoDyn press release
Scripps Research Institute-Designed Drug Candidate Significantly Reduces HIV Reactivation Rate

HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the virus and clinical progression to AIDS. But now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have shown that, unlike other antiretroviral therapies, a natural compound called Cortistatin A reduces residual levels of virus from these infected dormant cells, establishing a near-permanent state of latency and greatly diminishing the virus’ capacity for reactivation.

Published
11 July 2015
From
Scripps Research Institute
Could a Subdermal Implant Mean the End of HIV?

Findings published in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV.

Published
06 July 2015
From
Edge San Francisco
← First12345...84Next →

Filter by country